Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

Treatment of uncontrolled asthma with dupilumab, an anti–interleukin-4 and anti–interleukin-13 receptor monoclonal antibody, in addition to usual therapy, led to a rate of severe exacerbations that was approximately 50% lower than the rate with placebo.

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 378; no. 26; pp. 2486 - 2496
Main Authors:	Castro, Mario, Corren, Jonathan, Pavord, Ian D, Maspero, Jorge, Wenzel, Sally, Rabe, Klaus F, Busse, William W, Ford, Linda, Sher, Lawrence, FitzGerald, J. Mark, Katelaris, Constance, Tohda, Yuji, Zhang, Bingzhi, Staudinger, Heribert, Pirozzi, Gianluca, Amin, Nikhil, Ruddy, Marcella, Akinlade, Bolanle, Khan, Asif, Chao, Jingdong, Martincova, Renata, Graham, Neil M.H, Hamilton, Jennifer D, Swanson, Brian N, Stahl, Neil, Yancopoulos, George D, Teper, Ariel
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 28.06.2018
Subjects:	Adolescent Adult Age Anti-Asthmatic Agents - adverse effects Anti-Asthmatic Agents - pharmacology Anti-Asthmatic Agents - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Asthma Asthma - classification Asthma - drug therapy Biomarkers Blood Bronchodilator Agents - therapeutic use Bronchodilators Child Clinical medicine Committees Cytokines Double-Blind Method Drug dosages Drug Therapy, Combination Eosinophilia Eosinophilia - chemically induced Female Forced Expiratory Volume - drug effects Humans Immunotherapy Inflammation Injections, Subcutaneous - adverse effects Intention to Treat Analysis Interleukin 13 Interleukin 4 Intervention Leukocytes (eosinophilic) Male Medicine Middle Aged Monoclonal antibodies Patient safety Pharmaceuticals Population Questionnaires Receptors, Interleukin-4 - antagonists & inhibitors Respiratory function Safety Young Adult Los Angeles California United States > US California
ISSN:	0028-4793, 1533-4406, 1533-4406
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Treatment of uncontrolled asthma with dupilumab, an anti–interleukin-4 and anti–interleukin-13 receptor monoclonal antibody, in addition to usual therapy, led to a rate of severe exacerbations that was approximately 50% lower than the rate with placebo.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1804092